Tyler Coker
Primary Care · Buffalo, NYNPI 1407554983
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.5% of the total across 250 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 18.7% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 250 payments — averaging $18.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$864
- Jazz Pharmaceuticals Inc.$613
- Collegium Pharmaceutical, Inc.$581
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$475
- Averitas Pharma Inc.$416
- Catalyst Pharmaceuticals, Inc.$207
- plus $1K from 22 others
What the payments were for
- Food & beverage$4,44997%
- Education$1603%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 45 | $864 |
| Jazz Pharmaceuticals Inc. | 22 | $613 |
| Collegium Pharmaceutical, Inc. | 56 | $581 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 33 | $475 |
| Averitas Pharma Inc. | 14 | $416 |
| Catalyst Pharmaceuticals, Inc. | 9 | $207 |
| UCB, Inc. | 8 | $207 |
| Neurocrine Biosciences, Inc. | 9 | $199 |
| Scilex Pharmaceuticals Inc. | 10 | $170 |
| SK Life Science, Inc. | 6 | $146 |
| Lundbeck LLC | 7 | $135 |
| Vertex | 4 | $81 |
| Amneal Pharmaceuticals LLC | 5 | $80 |
| Kyowa Kirin, Inc. | 2 | $51 |
| Alnylam Pharmaceuticals Inc. | 3 | $48 |
| Teva Pharmaceuticals USA, Inc. | 2 | $39 |
| Eisai Inc. | 2 | $39 |
| Saluda Medical Americas, Inc. | 1 | $37 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Pfizer | 2 | $27 |
| Corium, LLC | 1 | $27 |
| Boston Scientific | 1 | $25 |
| Livanova USA, Inc. | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $21 |
| Impel Pharmaceuticals LLC | 1 | $19 |
| CSL Behring | 1 | $18 |
| Harmony Biosciences LLC | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Qutenza$154
How this compares
$4,609 in reported general payments places this provider in the 90th percentile of 239 primary care providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine | 165 | $48,323 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,622 | $48,321 |
| BelbucaBuprenorphine Hcl | 74 | $44,307 |
| Xtampza ErOxycodone Myristate | 52 | $38,036 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 529 | $23,763 |
| OxycontinOxycodone Hcl | 37 | $16,348 |
| Oxycodone Hcl | 615 | $14,132 |
| Oxymorphone Hcl ErOxymorphone Hcl | 31 | $13,864 |
| LyricaPregabalin | 18 | $9,937 |
| Pregabalin | 314 | $7,816 |
| MovantikNaloxegol Oxalate | 20 | $7,768 |
| Lidocaine | 67 | $7,342 |
| Morphine Sulfate ErMorphine Sulfate | 201 | $6,965 |
| Fentanyl | 38 | $6,856 |
| Gabapentin | 524 | $6,282 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $581 | $82,343126 claims |
| PfizerLyrica | $27 | $9,93718 claims |
| AbbVieSavella | $864 | $5,43711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 239 primary care providers in New York.
Other primary care in Buffalo
- Dorothy KleinertNew York$27K
- Stephanie KhanForest Hills$16K
- Albert MarcanoJackson Heights$15K
- Elizabeth GattmanJamestown$10K
- Vanessa WangFlushing$10K
- Elizabeth SmithWaterloo$9K
- Eric RodriguezSyracuse$7K
- Natalie Sommerville-BrooksBrooklyn$6K
- Lisa PlanetaNew York$6K
- Pao-Ju TsengFlushing$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.